

MicroVention Expands Executive Management Team to Drive Sales of Recently Launched Products

Kevin Riley Joins as Vice President North America Sales

ALISO VIEJO, Calif. -- September 26, 2002 -- MicroVention, Inc., a leading developer, manufacturer and marketer of minimally invasive treatments for cerebral vascular diseases, announced today Kevin Riley joined the company as Vice President North American Sales. He will report directly to Richard Cappetta, Vice President Worldwide Sales and Marketing.

Riley has more than 20 years of experience in the medical device industry working in executive sales and marketing level positions for such organizations as Stereotaxis, Angiotrax and Target Therapeutics. As Vice President, North American Sales and Marketing with Target Therapeutics, Riley was instrumental in the development of the interventional Neuroradiology market, building the sales and marketing departments, launching new product lines and bringing the company to an industry leadership position prior to its acquisition by Boston Scientific (BSX).

"Kevin's organizational development capabilities, results driven leadership and extensive industry specific physician relationships will help accelerate MicroVention as a force in the industry," said Robert Rosenbluth, President and CEO, MicroVention. "We are fortunate to add such a seasoned sales executive to our management team."

In the second quarter 2002, MicroVention launched its first endovascular coil embolization product, the MicroPlex Coil System, and recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Mark for its HydroCoil Embolization System. The technologies provide a minimally invasive approach for the treatment of cerebral aneurysms. MicroVention sells its products through its direct sales force in the U.S., France, Germany, the United Kingdom and through distributors in various other countries

A cerebral aneurysm is a ballooning of a weakened region of a blood vessel. If left untreated, the aneurysm may continue to weaken until it ruptures and bleeds into the brain. Approximately 2 to 5 percent of the U.S. population is estimated to have cerebral aneurysms- most of which go undetected. Each year approximately 150,000 patients worldwide are treated for cerebral aneurysms. Of this group, it is estimated that 20 percent are treated by endovascular coil embolization rather than traditional surgical approaches. Industry experts believe up to 75 percent of patients currently being treated for cerebral aneurysms could be treated with endovascular devices evidencing a near term market potential of approximately \$500 million. Endovascular embolization is one of the most rapidly growing vascular markets for medical technology.

About MicroVention, Inc.

MicroVention, Inc. (www.microvention.com) is a privately held medical device company dedicated to the development and commercialization of new catheter-based technologies for the endovascular treatment of peripheral and cerebral vascular diseases. The company has received 510(k) clearance and CE Mark for both its MicroPlex Coil System and the HydroCoil Embolization System, its next-generation endovascular coil system designed to treat cerebral aneurysms. In August 2002, MicroVention raised approximately \$19 million in late-stage financing.

MicroVention Contacts:

Robert Rosenbluth, President, CEO
William Hughes, Vice President, CFO
Ph. 949-768-1184
Fx. 949-768-0464